[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ShangHai Ji Ai Genetics & IVF Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100559232","live-birth-rate-between-icsi-and-aoa-and-icsi-alone-in-patients-with-severe-teratospermia-100559232",false,"NCT06561451","Live Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia","A Randomized Control Trial to Compare the Live Birth Rate Between Intracytoplasmic Sperm Injection and Artificial Oocyte Activation and Intracytoplasmic Sperm Injection Alone in Patients With Severe Teratospermia","Inclusion Criteria:\n\n1. Age of women 20-37 years at the time of ovarian stimulation for ICSI\n2. At least three matured oocytes Severe teratozoospermia: defined as abnormal sperm morphology ranging between 99-100%, including globozoospermia and tapered-head.\n\nExclusion Criteria:\n\n1. Presence of hydrosalpinx which is not surgically treated\n2. Undergoing preimplantation genetic testing\n3. Recurrent pregnancy loss (defined as two or more previous spontaneous pregnancy losses)\n4. Known uterine abnormality (e.g., uterine congenital malformation; untreated uterine septum, adenomyosis, or submucous myoma; endometrial polyps; or intrauterine adhesions)\n5. Abnormal parental karyotyping, or Medical conditions that assisted reproductive technology or pregnancy is contraindicated","ALL","20 Years","37 Years",{"count":20,"type":21},208,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare the live birth rate between intracytoplasmic sperm injection (ICSI) and artificial oocyte activation (AOA) vs intracytoplasmic sperm injection alone in patients with teratospermia. The hypothesis is the live birth rate following ICSI and AOA is significantly higher than that by ICSI alone in patients with teratospermia. This is a randomized controlled trial. Participants will be randomly assigned into one of the two groups:\n\nICSI+AOA group: a single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.\n\nICSI alone group: a single sperm will be injected within 4 hours after the follicular aspiration.",[27,28],"Male Infertility","Teratospermia","RECRUITING","2026-01-29",{"date":32,"type":33},"2026-02-02","ACTUAL",{"date":35,"type":33},"2024-08-30",{"date":37,"type":21},"2027-12-30",{"name":39,"class":40},"ShangHai Ji Ai Genetics & IVF Institute","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100464314","phase-3-comparison-of-the-euploid-rate-of-blastocyst-between-ppos-and-gnrh-antagonist-protocol-in-women-with-pcos-undergoing-pgt-a-100464314","NCT05326087","Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A","A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the PPOS (Progestin-primed Ovarian Stimulation) Protocol and the Gonadotropin-releasing Hormone (GnRH) Antagonist Protocol in Women With PCOS (Polycystic Ovary Syndrome) Undergoing PGT-A (Preimplantation Genetic Testing for Aneuploidy)","Inclusion Criteria:\n\n* Women age between 20 and 37 years.\n* Women diagnosed with PCOS according to the modified Rotterdam criteria: oligomenorrhea or amenorrhea, together with the presence of ≥12 antral follicles (≤9 mm) and\u002For ovarian volume \\>10 mL on transvaginal ultrasonographic scanning, and\u002For clinical\u002F biochemical hyperandrogenism. Other causes of hyperandrogenism and ovulation dysfunction-including tumours, congenital adrenal hyperplasia, hyperprolactinaemia and thyroid dysfunction-were excluded\n\nExclusion Criteria:\n\n* Presence of a functional ovarian cyst with E2\\>100 pg\u002FmL\n* Endometriosis grade 3 or higher\n* Repeated implantation failure (\\>=4 embryos replaced or \\>=2 blastocysts replaced without success)\n* Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)\n* Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease;\n* Recipient of oocyte donation\n* Presence of hydrosalpinx which is not surgically treated","FEMALE",{"count":51,"type":21},204,[53],"PHASE3","This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:\n\nAntagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.\n\nPPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger.\n\nThe primary outcome is the euploidy rate of blastocysts.",[56,57,58,59],"Preimplantation Genetic Testing","Progestin-primed Ovarian Stimulation","Polycystic Ovarian Syndrome","GnRH Antagonist","NOT_YET_RECRUITING",{"date":32,"type":33},{"date":63,"type":21},"2026-06-01",{"date":65,"type":21},"2028-12-01",{"name":39,"class":40},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":49,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":41},"100473616","phase-3-effect-of-gh-on-the-blastocyst-euploid-rate-in-ama-patients-100473616","NCT05447208","Effect of GH on the Blastocyst Euploid Rate in AMA Patients","A Randomized Control Trial to Investigate the Effect of Growth Hormone on the Euploid Rate of Blastocyst in Patients With Advanced Maternal Age","Inclusion Criteria:\n\n* Age ≥38; intended to undergo PGT-A\n* BMI in the normal range (18.50-24.0kg\u002Fm2)\n* Normal semen analysis for the male partner\n\nExclusion Criteria:\n\n* Endometriosis grade 3 or higher, untreat hydrosalpinx\n* Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)\n* Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease\n* History of endocrine disorder, autoimmune diseases or diagnosed thrombophilia\n* History of GH supplementation in the previous IVF treatment or taking other supplementary drugs used during stimulation; patients with absolute or relative contraindications to GH treatment, including active malignancy or history of cancer, diabetic retinopathy, diabetes mellitus, and chronic kidney disease.","38 Years",{"count":76,"type":21},400,[53],"This randomized trial aims to compare the euploid rate of blastocysts in AMA patients undergoing PGT-A (preimplantation genetic testing for aneuploidy) with or without growth hormone supplement.\n\nInfertile patients ≥38 years old will be recruited for study after informed consent if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:\n\nTreatment group: Women will receive growth hormone (GH) supplement before and during antagonist protocol for ovarian stimulation.\n\nControl group: Women will receive antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts.",[56,80,81],"Growth Hormone","Age, Parental","2025-02-07",{"date":84,"type":33},"2025-02-12",{"date":86,"type":33},"2022-08-01",{"date":88,"type":21},"2026-12-31",{"name":39,"class":40},""]